This site is intended for healthcare professionals in Belgium and Luxembourg.
1. Reblozyl® (luspatercept) [Summary of Product Characteristics (SmPC)]. Bristol Myers
Squibb Pharma EEIG, Dublin, Ireland. SmPC in French, SmPC in Dutch.
2. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap
ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.
3. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid
differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.
4. Musallam KM, Rivella S,
Vichinsky E, et al. Non-transfusion-dependent thalassemias. Hematologica. 2013;98(6):833-844.
For your adult patients with transfusion-dependent β-thalassemia
With Reblozyl®▼ —the first and only erythroid maturation agent—you can reduce patients’
Reblozyl®▼ is reimbursed in Belgium as of August 1st 2021 for the
treatment of adult patients:
The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25mg/kg every 21 days for
Reblozyl®▼ treatment will stop being reimbursed if:
▼This medicinal product is subject to additional monitoring. This will allow quick Identification of new
safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before
prescribing Reblozyl®▼, please refer to the SmPC.
View the Eu SmPC in French, SmPC in Dutch.